The resorcylic acid lactone hypothemycin selectively inhibits the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cells

Hidesuke Fukazawa, Yoshimi Ikeda, Mari Fukuyama, Takeshi Suzuki, Hiroshi Hori, Toru Okuda, Yoshimasa Uehara

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The resorcylic acid lactone hypothemycin has been shown to inactivate protein kinases by binding to a cysteine conserved in 46 protein kinases, including mitogen-activated protein kinase kinase (MEK), extracellular signal-regulated kinase (ERK) and platelet-derived growth factor receptor (PDGFR). We assessed the selectivity of hypothemycin in cellular contexts. Hypothemycin normalized the morphology and inhibited anchorage-independent growth of Ki-ras transformed normal rat kidney (NRK) cells with selectivity and potency comparable to or greater than that of the MEK inhibitor U0126. In Ki-ras-transformed and phorbol 12-myristate 13-acetate (PMA)-treated NRK cells, hypothemycin blocked ERK activation but showed a minimal effect on autophosphorylation of protein kinase D1 (PKD1), another kinase containing the conserved cysteine. Hypothemycin potently inhibited PDGFR autophosphorylation and activation of the MEK-ERK pathway in platelet-derived growth factor (PDGF)-treated NRK cells. However, the phosphoinositide-3-kinase (PI3K) pathway was only modestly attenuated. Hypothemycin also inhibited growth factor- and anchorage-independent growth of human cancer cell lines with a constitutively active MEK-ERK pathway. Although hypothemycin has the potential to inactivate various protein kinases, the results indicate that in intracellular environments, hypothemycin can inhibit the MEKERK axis with sufficient selectivity to normalize transformed phenotypes of cells dependent on this pathway.

Original languageEnglish
Pages (from-to)168-173
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume33
Issue number2
DOIs
Publication statusPublished - 2010 Feb

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Extracellular Signal-Regulated MAP Kinases
Lactones
Acids
Protein Kinases
Platelet-Derived Growth Factor Receptors
Kidney
Cysteine
MAP Kinase Kinase Kinases
1-Phosphatidylinositol 4-Kinase
hypothemycin
Platelet-Derived Growth Factor
Growth
Protein Binding
Intercellular Signaling Peptides and Proteins
Acetates
Phosphotransferases
Phenotype
Cell Line

Keywords

  • Hypothemycin
  • Protein kinase
  • Resorcylic acid lactone
  • Signal transduction

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

The resorcylic acid lactone hypothemycin selectively inhibits the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cells. / Fukazawa, Hidesuke; Ikeda, Yoshimi; Fukuyama, Mari; Suzuki, Takeshi; Hori, Hiroshi; Okuda, Toru; Uehara, Yoshimasa.

In: Biological and Pharmaceutical Bulletin, Vol. 33, No. 2, 02.2010, p. 168-173.

Research output: Contribution to journalArticle

Fukazawa, Hidesuke ; Ikeda, Yoshimi ; Fukuyama, Mari ; Suzuki, Takeshi ; Hori, Hiroshi ; Okuda, Toru ; Uehara, Yoshimasa. / The resorcylic acid lactone hypothemycin selectively inhibits the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cells. In: Biological and Pharmaceutical Bulletin. 2010 ; Vol. 33, No. 2. pp. 168-173.
@article{5f62e762fc074b6f82e0dc42fbaf8235,
title = "The resorcylic acid lactone hypothemycin selectively inhibits the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cells",
abstract = "The resorcylic acid lactone hypothemycin has been shown to inactivate protein kinases by binding to a cysteine conserved in 46 protein kinases, including mitogen-activated protein kinase kinase (MEK), extracellular signal-regulated kinase (ERK) and platelet-derived growth factor receptor (PDGFR). We assessed the selectivity of hypothemycin in cellular contexts. Hypothemycin normalized the morphology and inhibited anchorage-independent growth of Ki-ras transformed normal rat kidney (NRK) cells with selectivity and potency comparable to or greater than that of the MEK inhibitor U0126. In Ki-ras-transformed and phorbol 12-myristate 13-acetate (PMA)-treated NRK cells, hypothemycin blocked ERK activation but showed a minimal effect on autophosphorylation of protein kinase D1 (PKD1), another kinase containing the conserved cysteine. Hypothemycin potently inhibited PDGFR autophosphorylation and activation of the MEK-ERK pathway in platelet-derived growth factor (PDGF)-treated NRK cells. However, the phosphoinositide-3-kinase (PI3K) pathway was only modestly attenuated. Hypothemycin also inhibited growth factor- and anchorage-independent growth of human cancer cell lines with a constitutively active MEK-ERK pathway. Although hypothemycin has the potential to inactivate various protein kinases, the results indicate that in intracellular environments, hypothemycin can inhibit the MEKERK axis with sufficient selectivity to normalize transformed phenotypes of cells dependent on this pathway.",
keywords = "Hypothemycin, Protein kinase, Resorcylic acid lactone, Signal transduction",
author = "Hidesuke Fukazawa and Yoshimi Ikeda and Mari Fukuyama and Takeshi Suzuki and Hiroshi Hori and Toru Okuda and Yoshimasa Uehara",
year = "2010",
month = "2",
doi = "10.1248/bpb.33.168",
language = "English",
volume = "33",
pages = "168--173",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "2",

}

TY - JOUR

T1 - The resorcylic acid lactone hypothemycin selectively inhibits the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cells

AU - Fukazawa, Hidesuke

AU - Ikeda, Yoshimi

AU - Fukuyama, Mari

AU - Suzuki, Takeshi

AU - Hori, Hiroshi

AU - Okuda, Toru

AU - Uehara, Yoshimasa

PY - 2010/2

Y1 - 2010/2

N2 - The resorcylic acid lactone hypothemycin has been shown to inactivate protein kinases by binding to a cysteine conserved in 46 protein kinases, including mitogen-activated protein kinase kinase (MEK), extracellular signal-regulated kinase (ERK) and platelet-derived growth factor receptor (PDGFR). We assessed the selectivity of hypothemycin in cellular contexts. Hypothemycin normalized the morphology and inhibited anchorage-independent growth of Ki-ras transformed normal rat kidney (NRK) cells with selectivity and potency comparable to or greater than that of the MEK inhibitor U0126. In Ki-ras-transformed and phorbol 12-myristate 13-acetate (PMA)-treated NRK cells, hypothemycin blocked ERK activation but showed a minimal effect on autophosphorylation of protein kinase D1 (PKD1), another kinase containing the conserved cysteine. Hypothemycin potently inhibited PDGFR autophosphorylation and activation of the MEK-ERK pathway in platelet-derived growth factor (PDGF)-treated NRK cells. However, the phosphoinositide-3-kinase (PI3K) pathway was only modestly attenuated. Hypothemycin also inhibited growth factor- and anchorage-independent growth of human cancer cell lines with a constitutively active MEK-ERK pathway. Although hypothemycin has the potential to inactivate various protein kinases, the results indicate that in intracellular environments, hypothemycin can inhibit the MEKERK axis with sufficient selectivity to normalize transformed phenotypes of cells dependent on this pathway.

AB - The resorcylic acid lactone hypothemycin has been shown to inactivate protein kinases by binding to a cysteine conserved in 46 protein kinases, including mitogen-activated protein kinase kinase (MEK), extracellular signal-regulated kinase (ERK) and platelet-derived growth factor receptor (PDGFR). We assessed the selectivity of hypothemycin in cellular contexts. Hypothemycin normalized the morphology and inhibited anchorage-independent growth of Ki-ras transformed normal rat kidney (NRK) cells with selectivity and potency comparable to or greater than that of the MEK inhibitor U0126. In Ki-ras-transformed and phorbol 12-myristate 13-acetate (PMA)-treated NRK cells, hypothemycin blocked ERK activation but showed a minimal effect on autophosphorylation of protein kinase D1 (PKD1), another kinase containing the conserved cysteine. Hypothemycin potently inhibited PDGFR autophosphorylation and activation of the MEK-ERK pathway in platelet-derived growth factor (PDGF)-treated NRK cells. However, the phosphoinositide-3-kinase (PI3K) pathway was only modestly attenuated. Hypothemycin also inhibited growth factor- and anchorage-independent growth of human cancer cell lines with a constitutively active MEK-ERK pathway. Although hypothemycin has the potential to inactivate various protein kinases, the results indicate that in intracellular environments, hypothemycin can inhibit the MEKERK axis with sufficient selectivity to normalize transformed phenotypes of cells dependent on this pathway.

KW - Hypothemycin

KW - Protein kinase

KW - Resorcylic acid lactone

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=76049089947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76049089947&partnerID=8YFLogxK

U2 - 10.1248/bpb.33.168

DO - 10.1248/bpb.33.168

M3 - Article

C2 - 20118535

AN - SCOPUS:76049089947

VL - 33

SP - 168

EP - 173

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 2

ER -